Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Neuroscientific Biopharmaceuticals EV-to-EBITDA?
Neuroscientific BiopharmaceuticalsASX:NSB +10.34% EV-to-EBITDA is -7.41 as of Aug. 12, 2026. The stock has 1 warning sign investors should review. Among 398 Biotechnology companies, Neuroscientific Biopharmaceuticals ranks worse than 251256.03% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Neuroscientific Biopharmaceuticals's enterprise value is A$18.59 Mil.
Neuroscientific Biopharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-2.51 Mil. Therefore, Neuroscientific Biopharmaceuticals's EV-to-EBITDA for today is -7.41.
ASX:NSB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.41 Med: 0 Max: 0
Current: -7.41
ASX:NSB's EV-to-EBITDA is ranked worse than 100% of 398
companies
in the Biotechnology industry
Industry Median: 13.395
vs ASX:NSB: -7.41
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Neuroscientific Biopharmaceuticals's PE Ratio (TTM) for today is calculated as:
Neuroscientific Biopharmaceuticals's share price for today is A$0.064.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Neuroscientific Biopharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.015.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:NSB vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Neuroscientific Biopharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuroscientific Biopharmaceuticals EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neuroscientific Biopharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Neuroscientific Biopharmaceuticals's EV-to-EBITDA falls into.
Neuroscientific Biopharmaceuticals's current Enterprise Value is A$18.59 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Neuroscientific Biopharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-2.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuroscientific Biopharmaceuticals (ASX:NSB) has a EV-to-EBITDA of -7.41 as of Aug. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Neuroscientific Biopharmaceuticals. According to the industry distribution chart, Neuroscientific Biopharmaceuticals ranks #999999 out of 398 companies in the Biotechnology industry.
Is Neuroscientific Biopharmaceuticals' EV-to-EBITDA too high?
Neuroscientific Biopharmaceuticals' current EV-to-EBITDA is -7.41. Based on the distribution chart, Neuroscientific Biopharmaceuticals ranks #999999 out of 398 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Neuroscientific Biopharmaceuticals' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neuroscientific Biopharmaceuticals ranks #999999 out of 398 companies for EV-to-EBITDA. This places Neuroscientific Biopharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 13.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.40, based on 398 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Neuroscientific Biopharmaceuticals. For the Biotechnology industry, the median EV-to-EBITDA is 13.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuroscientific Biopharmaceuticals's current EV-to-EBITDA is -7.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuroscientific Biopharmaceuticals stock overvalued right now?
Neuroscientific Biopharmaceuticals (ASX:NSB) has a current EV-to-EBITDA of -7.41. The current EV-to-EBITDA is -7.41. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Neuroscientific Biopharmaceuticals (ASX:NSB), the current EV-to-EBITDA is -7.41 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neuroscientific Biopharmaceuticals Ltd is an Australian-based biotechnology company. The company is engaged in the development of diagnostic and treatments for neurodegenerative diseases through preclinical studies of patented technologies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:NSB has been successfully added to your 
